206A.T
PRISM BioLab Co.,LTD
グロース · 医薬品 · 医薬品 · JP
JPY 173.00
+1.17%Income statement
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | 684.0M | 677.0M | 305.0M |
| Cost of Revenue | 91.8M | 407.6M | 145.1M |
| Gross Profit | 41.1M | 269.8M | 160.5M |
| Operating Expenses | |||
| R&D Expense | — | — | — |
| SG&A Expense | 325.8M | 1.0B | 942.9M |
| General & Admin Expense | — | — | — |
| Selling & Marketing Expense | — | — | — |
| Other Expenses | — | — | — |
| Total Operating Expenses | 325.8M | 1.0B | 942.9M |
| Cost and Expenses | 1.5B | 1.5B | 1.1B |
| Operating Income (EBIT) | (822.0M) | (774.0M) | (782.0M) |
| Non-Operating | |||
| Interest Income | 3.1M | 5.3M | 356.0K |
| Interest Expense | — | — | — |
| Net Interest Income | — | — | — |
| Other Non-Op Income/Expense | 17.3M | 26.2M | (49.1M) |
| Non-Operating Income (excl Interest) | 14.5M | 21.5M | 432.0K |
| EBT (Pre-Tax Income) | (284.9M) | (831.3M) | (1.0B) |
| Income Tax Expense | 605.0K | 2.4M | 1.3M |
| Bottom Line | |||
| Net Income | (927.0M) | (833.0M) | (1.0B) |
| Earnings from Cont. Ops | — | — | — |
| Earnings from Discont. Ops | — | — | — |
| Bottom Line Net Income | (927.0M) | (833.0M) | (1.0B) |
| Per Share | |||
| Basic EPS | (¥25) | (¥23) | (¥34) |
| Diluted EPS | (¥25) | — | — |
| Revenue Per Share | ¥19 | ¥19 | ¥10 |
| Shares | |||
| Basic Shares Outstanding | 36.9M | 36.5M | 31.3M |
| Diluted Shares Outstanding | — | — | — |
| Profitability Metrics | |||
| EBITDA | — | — | — |
| D&A | — | — | — |
| EBIT | (822.0M) | (774.0M) | (782.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026